VBI Vaccines Inc (NASDAQ: VBIV) initiates enrollment in Phase 1/2 study of VBI-2902, its monovalent enveloped virus-like particle (eVLP), COVID-19 vaccine candidate.
- The adaptive 60-subject study will evaluate the safety, tolerability, and immunogenicity of VBI-2902, adjuvanted with aluminum phosphate.
- The Phase 1 portion of the study will evaluate a one- and two-dose regimen of a 5µg dose of VBI-2902. Depending on the enrollment rate, initial data from Phase 1 part is expected by the end of Q2 2021.
- The Phase 2 portion of the study is expected to be a dose-escalation extension study, assessing one- and two-dose regimens that will enroll an expanded adult population across three age cohorts, including 18-54, 55-65, and over 65.
- The company plans to start a Phase 1/2 study of the pan-coronavirus vaccine candidate, VBI-2901, later in 2021.
- Price Action: VBIV shares are up 3.07% at $3.19 in premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in